News

First Xarelto Bleeding Trial Underway

The first bellwether trial concerning controversial anticoagulant Xarelto has begun in the Eastern District of Louisiana. The late-April 2017 trial is one of four bellwether trials scheduled to take place throughout this spring and summer. The cases all similarly allege that the drug’s manufacturer Janssen Pharmaceuticals did not adequately warn patients about the uncontrollable bleeding risks associated with Xarelto and that it withheld certain safety information regarding the lack of a bleeding antidote.

Many plaintiffs in the Xarelto litigation are represented by Grant & Eisenhofer, a plaintiffs’ firm involved in the Bellwether Selection Committee and co-lead of the Law & Briefing Committee. If you or a loved one experienced complications from taking the drug Xarelto, please call us at (888) 984-7988 for a confidential evaluation of your potential claim.

Failure to Warn Claims Survive as Makers of Xarelto Denied Summary Judgment

With more than 16,000 Xarelto bleeding lawsuits pending in the Eastern District of Louisiana, two motions for partial summary judgment have been denied by U.S. District Judge Eldon Fallon, the judge presiding over the Xarelto multidistrict litigation, or MDL. The motions were filed by manufacturers of the blood-thinner drug, Johnson & Johnson subsidiary Janssen Pharmaceuticals, seeking to dismiss claims that it failed to warn consumers about the risk of severe bleeding problems associated with Xarelto. Judge Fallon’s denial of these motions allows two pending bellwether cases to proceed. The bellwether cases are scheduled to go to trial on April 30, 2017 and May 30, 2017.

Many plaintiffs in the Xarelto litigation are represented by Grant & Eisenhofer, a plaintiffs’ firm involved in the Bellwether Selection Committee and co-lead of the Law & Briefing Committee. If you or a loved one experienced complications from taking the drug Xarelto, please call us at (888) 984-7988 for a confidential evaluation of your potential claim.

FDA Calls Out St. Jude for Downplaying Defibrillator Problems

According to a warning letter sent by the FDA to Abbott Laboratories (owner of medical device manufacturer St. Jude Medical, responsible for 400,000 implantable defibrillators), reported that St. Jude downplayed defibrillator battery problems and sold defective devices for years before issuing a recall in October 2016. The defect stems from the lithium-based batteries that power the defibrillators being prone to lithium build-up, or “clusters,” which can cause premature battery failure. In the warning letter, the FDA noted that St. Jude had not taken enough action to remedy the faulty battery issues that led to the recall, and required St. Jude to provide a plan for correcting the problems within 15 days.

If you or a loved one received a St. Jude Medical Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator implant and experienced complications, please call us at (888)-984-7988.

Hyland’s Teething Tablets Recalled Due to Mislabeling

Just three months after the FDA communicated a safety alert in January 2017, the federal regulator has now announced that a nationwide recall was issued for Hyland’s Baby Teething Tablets and Hyland’s Baby Nighttime Teething Tablets by manufacturer Standard Homeopathic Company. The products, marketed to soothe pain associated with teething, have been reported in association with adverse side-effects including fever, lethargy, vomiting, shortness of breath, and even death for at least 10 children who used the tablets. The FDA notes that Hyland’s teething tablets contain unsafe levels of belladonna that may differ from the products’ labeling and represent a “serious health hazard to children.”

If you or a loved one used Hyland’s teething tablets on your baby and your baby exhibited adverse side-effects, please contact us by calling (888) 984-7988 so we can confidentially discuss the legal options available to you.

Florida Woman Files Lawsuit over Ethicon Physiomesh Complications

In a new product liability lawsuit filed against Ethicon, a Florida woman alleges that the company’s hernia repair product Physiomesh Flexible Composite Mesh is defective and poses an unreasonable risk of severe adverse reactions among patients. The plaintiff experienced painful complications with the Physiomesh used in a hernia repair, including the need for revision surgery. She maintains that neither she nor her doctor was warned of the dangerous risks associated with the Physiomesh.

This case joins several other Ethicon Physiomesh lawsuits filed in recent months alleging similar complications. If you or a loved one received an Ethicon Physiomesh Flexible Composite Mesh product during hernia repair surgery and have experienced complications or underwent revision surgery, please call us at (888) 984-7988.

Real Time Analytics